

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/16		A1	(11) International Publication Number: WO 97/14408 (43) International Publication Date: 24 April 1997 (24.04.97)
<p>(21) International Application Number: PCT/SE96/01091</p> <p>(22) International Filing Date: 3 September 1996 (03.09.96)</p> <p>(30) Priority Data: 9503672-9 19 October 1995 (19.10.95) SE</p> <p>(71) Applicant (for all designated States except US): BIOGRAM AB (SE/SE); P.O. Box 50577, S-202 15 Malmö (SE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): GUSTAFSSON, Nils-Ove (SE/SE); Hippodromvägen 7, S-246 50 Löddeköpinge (SE). LAAKSO, Timo (SE/SE); Boltensterns väg 33D, S-236 38 Höllviken (SE). FYHR, Peter (SE/SE); Löjtnantsvägen 9, S-237 32 Bjärred (SE). JÖNSSON, Monica (SE/SE); Sigvard Grubbes gata 1, S-230 40 Bara (SE).</p> <p>(74) Agent: AWAPATENT AB; P.O. Box 45086, S-104 30 Stockholm (SE).</p>		<p>(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	

(54) Title: SUSTAINED RELEASE PARTICLES

(57) Abstract

A method of preparing parenterally administrable sustained release microparticles, which comprises preparing core particles in an aqueous medium that is essentially free from organic solvent, a biologically active substance being entrapped therein during or after said preparation, drying the core particles and coating the same with a release-controlling polymer by air suspension technique so as to create a shell on the core particles without any detrimental exposure of the active substance to organic solvent. Microparticles obtainable by such a method.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Malta	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SUSTAINED RELEASE PARTICLES**Technical field**

The present invention is within the field of sustained release particles for parenteral administration of 5 biologically active substances, especially drugs. More specifically it relates to a new preparation method for such particles containing a biologically active substance as well as to new sustained release particles obtainable thereby.

10 Background of the invention

Many drugs have to be administered by injection since they are either degraded or absorbed inefficiently when given for instance orally or nasally or by the rectal route. A drug formulation intended for parenteral use 15 has to meet a number of requirements in order to be approved by the regulatory authorities for use in humans. Thus, it has to be biocompatible and biodegradable and all substances used and their degradation products should be non toxic. In addition thereto, particulate drugs intended for injection have to be small enough to pass 20 through the injection needle, which preferably means that they should be smaller than 200 µm. The drug should not be degraded to any large extent in the formulation during production or storage thereof or after administration and 25 should be released in a biologically active form with reproducible kinetics.

One class of polymers which fulfils the requirements as to biocompatibility and biodegradation to harmless end products are the linear polyesters based on lactic acid, 30 glycolic acid and mixtures thereof. In the text below said polymers will also be referred to as PLGA. PLGA is degraded by ester hydrolysis to lactic acid and glycolic acid and has been shown to display excellent biocompatibility. The innocuous nature of PLGA is furthermore exemplified by the approval of several parenteral sustained 35

release formulations based on these polymers by regulatory authorities, like the US Food and Drug Administration.

Parenterally administrable sustained release products on the market today based on PLGA include Decapeptyl™ (Ibsen Biotech), Prostap SR™ (Lederle), Decapeptyl® Depot (Ferring) och Zoladex® (Zeneca). The drugs of these formulations are all peptides. In other words they consist of amino acids condensed to a polymer with a relatively low degree of polymerisation and they do not have any well defined three-dimensional structure. This in turn generally permits the use of rather harsh conditions during preparations of said products. For example extrusion and subsequent size reduction can be used, which techniques should not be permissible in connection with proteins since they generally do not withstand such harsh conditions.

Consequently there is also a need for sustained release formulations for proteins. Proteins are similar to peptides in that they also consist of amino acids, but the molecules are larger and most proteins are dependant on a well defined three-dimensional structure as to many of their properties, including biological activities and immunogenicity. Their three-dimensional structures can relatively easily be destroyed, for example by high temperatures, surface induced denaturation and, in many cases exposure to organic solvents. Thus, a very serious drawback in connection with the use of PLGA, which is an excellent material per se, for sustained release of proteins is the requirement to utilize organic solvents to dissolve said PLGA, with the associated risk of compromising the stability of the protein.

Despite large efforts aiming at a modification of the PLGA technology in order to avoid this inherent problem with protein instability during the preparation process the progress in this field has been very slow and as yet no protein products have appeared on the market based

on PLGA technology. The main reason therefore probably is that the three-dimensional structures of most proteins are too sensitive to withstand the preparation procedures used and/or being stored in a PLGA-matrix.

5 The most commonly used technique at present for entrapping water soluble substances such as proteins and peptides is the use of multiple emulsion systems. The drug substance is dissolved in a water or buffer solution and then mixed with an organic solvent, immiscible with
10 water, containing the dissolved polymer. An emulsion is created having the water phase as the inner phase. Different types of emulsifiers and vigorous mixing are often used to create this first emulsion. Said emulsion is then transferred, under stirring, to another liquid, typically
15 water, containing another polymer, for example polyvinylalcohol, giving a triple w/o/w-emulsion. The microspheres are then hardened in some way. The most commonly used way is to utilize an organic solvent having a low boiling point, typically dichloromethane, and to evaporate the solvent. If the organic solvent is not fully immiscible with water, a continuous extraction procedure can be used by adding more water to the triple emulsion.
20 A number of variations of this general procedure are also described in the literature. In some cases the primary emulsion is mixed with a non-aqueous phase, for instance
25 silicon oil. Solid drug materials rather than dissolved drugs can also be used.

30 The release profiles of proteins from microspheres prepared by said method often show a fast initial release followed by a slower phase. Said slower phase can be followed by a third phase of faster release.

35 PLGA microspheres containing proteins are disclosed in WO-A1-9013780, the main feature of which is the use of very low temperatures during the manufacture of the microspheres in order to retain high biological activity of the proteins. The activity of encapsulated superoxide dismutase was measured but merely on the portion released

from the particles. This method has been used to produce PLGA microspheres containing human growth hormone in WO-A1-9412158 by dispersing human growth hormone in methylene chloride containing PLGA, spraying the obtained dispersion into a container with frozen ethanol with a layer of liquid nitrogen thereabove in order to freeze the droplets and allow them to settle in the nitrogen on to the ethanol. The ethanol is then thawed and the microspheres start to sink in the ethanol where the methylene chloride is extracted into the ethanol and the microspheres are hardened. This approach may be able to retain the stability of proteins better than most other processes for entrapping proteins in PLGA microspheres. However, this still remains to be unequivocally demonstrated for other proteins.

However, in the earlier mentioned methods based on encapsulation with PLGA the active substances are subjected to an organic solvent and this is generally detrimental to the stability of a protein. In addition thereto, the emulsion processes referred to above are complicated and likely to be problematic to scale up to an industrial scale. Furthermore, many of the organic solvents used in many of these processes are fraught with environmental problems and their high affinities for the PLGA polymer make removal difficult.

A parenterally administrable sustained release formulation should be able to control the release of the entrapped drug in an accurate way. In many of the systems based on PLGA the release of the active ingredient is largely dependent on the amount of drug substance incorporated into the microparticle, due to the formation of channels in the microparticles at higher drug loadings. This also contributes to a high initial burst at high drug loading.

A well known way of controlling the release of small molecules from a solid core is to apply a coating that produces a rate controlling film on the surface of the

core. This is a general method of controlling the release rate of drugs to be administered by the oral route. One way of applying similar coats is by the use of air suspension technology. However, in connection with coating 5 particles for use in parenteral administration, which particles are generally of a size below 200 μm , and often smaller, generally severe problems are encountered. Such problems can be an increased tendency for particles to agglomerate and problems with static electricity disturbing 10 the manufacturing process.

Some different ways of coating particles of such small sizes are dispersion of the drug in a solution of the coating material and subsequent spray drying and a number of coacervation methods where a dissolved polymer 15 is used to encapsulate the core material in different ways. However, all these methods would expose a protein to the organic solvent used to dissolve the PLGA. A method where a fluidized bed is used in the coating of microparticles is disclosed in US 4 568 559. Here a 20 solid, dry composite admixture is prepared from a uniform dispersion of an active ingredient of a film-forming polymer, the admixture then being ground and the resulting particles being sieved to obtain a size distribution of 1-150 μm . The core particles are then coated in a fluidized bed, a prerequisite, however, being that the same, or substantially the same, film-forming polymer material 25 is used both for the preparation of the composite core and the coating to provide for bonding of the wall coating of the film-forming polymer to the core material. Thus, 30 this method does not either eliminate the problem of exposing the protein to organic solvents if the film-forming polymer is PLGA or any other polymer that is not water soluble.

Thus, a method of producing parenterally administrable sustained release formulations for sensitive substances, for instance proteins, with the following properties would be highly desirable:

that can control the release rate of the entrapped substances within wide margins, typically from one or a few days to at least around one month;

5 that enables the production to be carried out with standard pharmaceutical equipment and which can be used from small scale manufacture to full scale production;

10 that makes it possible to eliminate, or minimise, the exposure of the active ingredient to organic solvents; and

that is completely biodegradable and has a surface of a biocompatible material.

15 **Description of the invention**

According to the present invention it has been found possible to prepare a parenterally administrable sustained release formulation with the characteristics referred to above. The new method claimed thus makes it possible to take advantage of the excellent biocompatibility and release controlling properties of PLGA while avoiding or minimising the exposure of for instance a protein to be formulated to organic solvents. However, the invention is not restricted to the use of PLGA only as a coating material or the use of a protein only as the active ingredient. Rather the invention is applicable to the use of any polymer that is film-forming, biodegradable and release-controlling, especially a polymer for which organic solvents have hitherto been utilized. Another prerequisite for a polymer is of course that it is pharmaceutically acceptable, which requirement is applicable also to all other materials or ingredients used in the formulation. Furthermore, the invention is useful for all active substances which may be utilized in parenteral administration. Primarily, however, the invention presents a solution to the previously described problem with

active substances sensitive to or instable in organic solvents.

Briefly the invention is based on the idea on entrapping the active ingredient in microparticles without using any organic solvent, working up the microparticles to the dry state and subsequently coating the microparticles with a biodegradable polymer using an air suspension technique to remove, very rapidly, any organic solvent used for the polymer coating to avoid any substantial exposure of the active substance to organic solvent.

More specifically, according to a first aspect of the invention, a method is provided of preparing parenterally, preferably injectionally, administrable, sustained release microparticles containing a biologically active substance, especially a substance that is instable in the presence of an organic solvent, said method comprising preparing core particles from a biodegradable material in an aqueous medium that is essentially free from organic solvent, the biologically active substance being entrapped therein during or after said preparation, drying the core particles containing said active substance, optionally after a washing step to remove any excess of active substance, and coating the core particles with a film-forming, biodegradable, release-controlling polymer by air suspension technique so as to create a shell of said polymer on the core particles without any detrimental exposure of the active substance to organic solvent.

Since the method is primarily intended for the preparation of microparticles adapted for administration by injection, the microparticles preferably have an average diameter in the range of 10-200 μm , more preferably 20-100 μm , and most preferably smaller than 60 μm , e.g. 10-60 μm or 40-60 μm .

A preferable core particle material is a starch or a chemically or physically modified starch. Such materials are previously known per se in this technical field, and therefore reference can be made to the prior art concern-

ing details about such starches. It can, however, be added that microparticles prepared from starch can be designed so as to be dissolved by α -amylase, an enzyme present in serum and extracellular fluid, and as the end 5 degradation product is glucose, starch microparticles can fulfil the requirement of biodegradability.

The preferred polymers for the shell are alifatic polyesters (e.g. homopolymers) or copolymers from α -hydroxy acids or cyclic dimers of α -hydroxy acids.

10 Said α -hydroxy acid is preferably selected from the group consisting of lactic acid and glycolic acid. In other words a preferred homopolymer can be for instance polylactic acid or polyglycolic acid, while a preferred copolymer can be a lactic acid/glycolic acid copolymer.

15 The cyclic dimers are preferably selected from the group consisting of glycolides and lactides.

However, as indicated above, other biodegradable polymers could also be used provided the polymer is able 20 to form a film with the desired properties as to mechanical stability and release controlling properties, such as permeability to the active ingredient or the formation of pores. These properties could be fulfilled by the polymer itself or by including other substances in the coating. The coating material used could of course also be a mixture 25 of two or more of the polymers referred to. Furthermore, said polymers may also be used in the form of their salts.

The biologically active substance can be entrapped 30 in the microparticles without any use of organic solvent in several ways. An especially preferred way is the use of a so called aqueous two phase system technique, which is previously known per se. Said method is for instance disclosed in US Patent No. 4 822 535, which means that details about said technique can be found therein. An- 35 other way involves the preparation of core microparticles which are able to absorb water in a separate process, removal of any organic solvent used and loading the ob-

tained microparticles with the active substance by exposing the dry microparticles to a solution of said active substance to have the solution absorbed by the microparticles, which are subsequently dried.

5 The drying of the core particles can be accomplished by any appropriate means, for example by spray drying, freeze drying or vacuum drying. In order to remove excess of active substance the microparticles or cores could also be washed prior to the drying step.

10 The core particles containing the active substance are subsequently coated by an air suspension technique which enables the creation of a shell of the polymer on the core particles without any substantial or detrimental exposure of the active substance to organic solvent. Said 15 air suspension technique can be any method that is classified as an air suspension method and is able to apply a satisfactory coating. Preferred examples of such methods are methods wherein a fluidized bed or a so called spouted bed are utilized or the so called Wurster process, which method are all previously known per se and need not be described in detail here. Thus, the term "air suspension method" as used herein means any method where solid particles are suspended in an upwardly moving stream of gas. Said gas could be any gas capable of 20 evaporating the solvent used and need not necessarily be air in spite of the term "air" suspension.

25 However, in connection with the air suspension technique it has been found that the problems with sensitive active substances and their exposures to organic solvents 30 are eliminated, or essentially reduced, while preferably using a high flow rate of the air, or gas, sufficient to accomplish the desired result.

According to a preferable embodiment of the method claimed the polymer is applied on to the core particles from a solution, a pseudolatex or an emulsion thereof. In this connection it should be noted that an organic solvent can be utilized as the solvent for the polymer, as

it has unexpectedly been found that by the new method according to the invention the active substance is not influenced to any substantial extent by the presence of such a solvent.

5 However, another preferable embodiment of the invention is represented by the case where said coating solution contains water, said pseudolatex is a pseudolatex of the polymer in water and said emulsion is an emulsion where one of the phases is a water phase. In the case of
10 a mixture of different polymers, they can be present in different phases of an emulsion. Thus, it has been found that the presence of water can eliminate, or substantially reduce, the build up of static electricity during the coating procedure, and an especially preferred embodiment in this respect is the use of an emulsion where
15 one of the phases is a liquid of the polymer in a solvent for said polymer and the other phase is water. Last-mentioned emulsion is furthermore useful in a more general aspect, as will be described more specifically below
20 and which also represents another aspect of the invention.

Another preferable embodiment of the invention is represented by the case wherein one or more stabilizing agents are incorporated in the particles during the
25 preparation thereof. The nature of such a stabilizing agent is of course dependent on the specific active substance to be stabilized and said agent is chosen in line with known principles.

30 Additives can also be incorporated into the release-controlling polymer shell during the application thereof. Preferable examples of such additives are film property modifying agents and release controlling agents. Examples as to the first category are plasticizers, e.g. triethylcitrate, triacetin, polyethyleneglycol, polyethyleneoxide etc, while release controlling agents can be for instance inorganic bases (e.g. sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, etc), organic

5 bases (e.g. ethanol amine, diethanole amine, triethanole amine, lidocaine, tetracaine, etc,), inorganic acids (e.g. ammoniumsulfate, ammonium chloride, etc), organic acids (e.g. citric acid, lactic acid, glycolic acid, ascorbic acid, etc), and solid soluble substances which upon release create pores in the coating (e.g. crystals of sodium chloride, glucose, mannitol, sucrose, etc).

10 Additives to be included in the case where an emulsion or a pseudolatex is created are for instance emulsifiers.

15 The required amount of coating material depends on for example the size of the microcapsules, the composition of the coating and the desired release characteristics. Typical amounts are, however, 1-200 percent by weight, preferably 5-100 percent by weight, based on the weight of the core.

20 After the application of the coating controlling the release of the entrapped active substance additional materials could also be applied, e.g. sprayed, on to the microparticles in order to further modify the properties thereof or to facilitate the handling thereof. Examples of such materials are mannitol, sucrose and sodium chloride.

25 As already indicated above the invention is especially interesting in connection with proteins, peptides and polypeptides or other drugs or biologically active substances which are sensitive to or instable in the presence of organic solvents. However, generally the invention is not limited to the presence of such substances 30 only as the inventive idea is applicable to any biologically active substance which can be used for parenteral administration. Thus, in addition to sensitive or instability problems the invention may well be of special interest in cases where it would otherwise be difficult to 35 remove solvents or where toxicological or other environmental problems might occur.

According to a second aspect of the invention there is also provided parenterally administrable sustained release microparticles per se, which comprise a) core particles of a biodegradable material with the active substance entrapped therein, which core particles have been prepared in an aqueous medium essentially free from organic solvent, and b) a shell of a film-forming, biodegradable, release-controlling polymer on said core particles, which shell has been applied on said core particles by air suspension technique.

As to preferable embodiments and examples of materials and techniques to be used in connection therewith, reference is made to all embodiments and examples specified above and which will not be repeated once more.

According to a third aspect of the invention there is also provided a method of coating small particles in general, preferably microparticles as defined above, by air suspension technique, which method comprises applying on said particles, by air suspension technique, a coating emulsion of a coating material where one of the phases is a liquid of the coating material in a solvent and the other phase is water.

Thus, by such a method it has been found possible to eliminate or reduce problems associated with static electricity in air suspension coating of small particles.

The background of this aspect of the invention is as follows. The technology of air suspension coating of tablets, granules and small particles is well known. When the coating is made with the coating material in an organic solvent static electricity can be a problem. This problem is more pronounced when coating small particles. Thus, small particles have a tendency of adhearing to the walls of the coating chamber and also to each other, making the problem with unwanted agglomeration more severe. Particles sticking to the wall of the coating apparatus can cause uneven coating in the batch, lower yield and a less controllable process.

For some coating polymers the use of an aqueous dispersion of latex or pseudolatex eliminates or reduces the problems associated with static electricity. It has not been possible to use a latex dispersion for all coating 5 polymers with the same quality of the film being obtained from organic solvent based system. This aspect of the invention makes it possible to circumvent this problem.

In this context it should be added that the particles in connection with the invention are not specifically limited as to size or composition. Thus, it may be 10 a drug substance or particles containing drug substances, fertilizers, etc.

The coating material is any coating material, e.g. a film-forming polymer, which could be used in air suspension coating and which is soluble in a solvent not totally miscible with water. Examples of coating materials 15 are the polymers specifically referred to above. Examples of appropriate solvents are higher alcohols, esters, ethers, ketones, chlorinated hydrocarbons, aliphatic hydrocarbons and aromatic hydrocarbons. 20

The coating emulsion is made by mixing an aqueous phase with an organic phase. The coating material is dissolved in the organic phase. The emulsification step can be carried out by any of the conventional dispersing procedures, such as intermittent agitation, mixing with a 25 propeller, turbine mixer or magnetic mixer, colloid mill process, homogenisation process or sonification process. The organic phase can be either the internal or the external phase.

An emulsifier may be added to stabilise the emulsion. Preferable examples thereof are anionic surfactants or non-ionic surfactants. These emulsifiers can be used 30 alone or in combination.

The coating equipment used according to this aspect 35 of the invention, as well as in connection with the first aspect of the invention, could be any type of air suspen-

sion equipment capable of coating particles, especially small particles.

Examples

The invention will now be exemplified by the following 5 non-limiting examples wherein microparticles containing BSA, which is the most extensively used model protein for systems like this due to its well known characteristics and moderate cost, are coated with a layer comprising poly(lactide-co-glycolide). Furthermore, microparticles 10 containing human insulin are coated, since insulin is known to be a sensitive protein and the biological activity of the final preparation can easily be assayed in vivo. The microparticles are prepared for example in accordance with technique disclosed in US Patent No. 4 15 822 535. The coating is applied with commercially available equipment and the parameters set in the examples should merely be regarded as guidelines, since adjustments may be needed in many cases in order to obtain optimal conditions for the coating.

20 **Procedure for preparing the core particles**

Example 1

Two-phase immobilisation in accordance with US Patent No 4 822 535.

1. Weigh out 80 g of starch (Amioca 50, National Starch) 25 and suspend in 320 g of 50 mM sodium bicarbonate buffer pH 9,8.
2. Heat the suspension until the starch has been totally dissolved.
3. Cool the solution to 50°C.
- 30 4. Add 96 ml of a 9,26% BSA solution (room temperature) in 50 mM sodium bicarbonate buffer pH 9,8 and stir for 10 seconds.
5. Add starch-protein solution to 800 ml of a 20 w/w% polyethylene glycol solution in 50 mM sodium bicarbonate buffer pH 9,8 (room temperature, Av. Mol. Wt. 35 20000), under continuous stirring.

6. After 2 minutes, add 3200 ml of a 40 w/w% polyethylene glycol solution in 50 mM sodium bicarbonate buffer pH 9,8 (room temperature, Av. Mol. Wt. 20000), under continuous stirring.
- 5 7. Stir for 24h.
8. The obtained microparticles are washed and vacuum dried.
9. The dry microparticles are sieved through a 160 μm mesh.

10 **Example 2**

1. Weigh out 80 g of starch (Amioca 50, National Starch) and suspend in 420 g of water.
2. Heat the suspension until the starch has been totally dissolved.
- 15 3. Cool the solution to 50°C.
4. Add the starch solution to 800 ml of a 20 w/w% polyethylene glycol solution in water (room temperature, Av. Mol. Wt. 20000 D), under continuous stirring.
5. After 2 minutes, add 3200 ml of a 40 w/w% polyethylene glycol solution in water (room temperature, Av. Mol. Wt. 20000 D), under continuous stirring.
- 20 6. Stir for 24h.
7. The obtained microparticles are washed and vacuum dried.
- 25 8. The dried microparticles are impregnated with a 5% (w/w) BSA solution in water. Equal weight of particles and BSA-solution are used.
9. After 3h the particles are freeze dried.
10. The dried microspheres are sieved through a 160 μm sieve.

PRECEDURE FOR PREPARING THE CORE PARTICLES

Example 3

1. Weigh out 30 g of starch (Amioca 50, National Starch) and suspend in 320 g of 50 mM sodium bicarbonate buffer pH 9,3.
- 35 2. Heat the suspension until the starch has been totally dissolved.

3. Cool the solution to 50°C.
4. Centrifuge 2511 ml of Monotard® from Novo Nordisk corresponding to 8.89 g insulin. Wash the insulin once with 500 ml of a buffer containing 0.15 M NaCl,
- 5 1 mM ZnCl₂ and 10 mM Sodium acetate with a pH of 7.3 and centrifuge again. Mix the insulin with the starch solution and stir for 10 seconds.
- 10 5. Add starch-protein solution to 800 ml of a 20 w/w% polyethylene glycol solution in 50 mM sodium bicarbonate buffer pH 9,8 (room temperature, Av. Mol. Wt. 20000), under continuous stirring.
- 15 6. After 2 minutes, add 3200 ml of a 40 w/w% polyethylene glycol solution in 50 mM sodium bicarbonate buffer pH 9,8 (room temperature, Av. Mol. Wt. 20000), under continuous stirring.
7. Stir for 24h.
8. The obtained microparticles are washed and vacuum dried.

20 **Procedure for preparing the shell**

Example 4

Procedure for preparing the coating solution

1. Weigh out 200 g of poly(lactide-co-glycolide 75/25) Resomer RG756 from Boeringer Ingelheim.
- 25 2. Add 10 g of triacetin.
3. Dissolve it in 3123 g of acetone.

Procedure for applying the coating

1. 500 g of starch microparticles containing 3,5% BSA are loaded in a Glatt GPCG 6" Wurster.
- 30 2. The following conditions of the Wurster are set:

Atomization pressure	3 bar
Atomizing nozzle	0,8 mm
Inlet temperature	38-40°C
Outlet temperature	33-37°C
Product temperature	34-38°C
Air velocity	3,2-3,4 m/s
Flow of coating solution	4,4 ml/min

3. Recover the coated product.

Example 5

Procedure for preparing the coating solution

1. Weigh out 200 g of poly(lactide-co-glycolide 50/50)
5 Resomer RG504H from Boeringer Ingelheim.

2. Dissolve it in 3133 g of acetone.

Procedure for applying the coating

1. 500 g of starch microparticles containing 3,5% BSA are
loaded in a Glatt GPCG 6" Wurster.
10 2. The following conditions of the Wurster are set:

Atomization pressure	3 bar
Atomizing nozzle	0,8 mm
Inlet temperature	38-40°C
Outlet temperature	33-37°C
15 Product temperature	34-38°C
Air velocity	3,0-3,2 m/s
Flow of coating solution	4,4 ml/min

3. Recover the coated product

Example 6

20 Procedure for preparing the coating solution

1. Weigh out 40 g of poly(D,L lactide) Resomer R104 and
40 g of poly(lactide-co-glycolide 75/25) Resomer RG756
from Boeringer Ingelheim.
2. Dissolve it in 1252 g of ethyl acetate.
25 3. Mix 2504 g of water with 1,6 g of Tween 80.
4. Mix the polymer solution and the water solution using
an Ystral-turrax mixer at high speed.

Procedure for applying the coating

1. 100 g of starch microparticles containing 2,7% BSA are
30 loaded in a Hüttlin Kugelcoater HKC005.
2. The following conditions for the kugelcoater are set:

Atomization pressure	0,3 bar
Microclimate pressure	0,4 bar
Atomizing nozzle	0,6 mm
15 Inlet temperature	25-27°C
Outlet temperature	20-24°C
Flow of coating solution	5-7 g/min

3. After coating with PLGA, 200 g of a water solution containing 10 w/w% mannitol and 0,4 w/w% Tween 80 are sprayed onto the particles with a flow of 3,5 g/min.
4. Recover the coated product.

5 **Method for in vitro release**

The in vitro release is monitored by weighing up 70 mg of coated product and adding 1,5 ml of buffer solution to a polypropylene eppendorf tube. The release buffer consists of sodium phosphate 30 mM, pH 7,4, I-0,154 with 10 sodium chloride, 1 mM calcium chloride, α -amylase 72 U/l, and sodium azide 0,02%. At proper intervals 1 ml of buffer is removed and fresh buffer is added to the samples in order to maintain the correct pH. The tubes are slowly rocked in 37°C. The protein and starch concentrations are 15 measured together with pH.

Method for in vivo release

10 SPF female rats (9-10 weeks, 170-180 g) were used for studying the in vivo release of BSA from the coated microspheres. 200 μ l of a suspension containing 163 mg/ml 20 of microparticles prepared according to example 6 were injected subcutaneously in the neck. The vehicle for the injection was physiological sodium chloride solution containing 3% of sodium carboxymethylcellulose as suspension aid. The injection was made using a 21 G needle.

25 As a control group, non coated microspheres were given to 3 animals for comparison. The dose of BSA was four times higher in the coated preparation than in the non coated preparation.

30 Blood samples for measuring BSA were taken from the orbital plexus day 0 before dosing and in the afternoon, and at the same times of the day on day 1, 2, 3, 4, 5, 6 and 7. Five hundred μ l of blood were taken and analysed for BSA in serum. The BSA concentrations in serum were analysed using an ELISA method based on a commercially available antibody (Dakopatts) reacting with bovine, but not rat, albumin.

Example 7

The procedure for preparing the coating solution was similar to that of Example 6.

Procedure for applying the coating

5 100 g of starch microparticles containing 9.3% of insulin (Monotard® from Novo Nordisk) are loaded in a Hütlin Kugelcoater HKC005.

The rest of the coating procedure is similar to that of Example 6.

10

Method for in vivo release

10 SPF female rats (9-10 weeks, 170-180 g) were used for studying the biological effects of the preparation of Example 7. Three days before injection with the test substance, the rats were treated with 65 mg/kg of streptozotocin in order to induce diabetes. Streptozotocin was dissolved in a 1% citrate buffer at pH 4.5 maximally two minutes before injection.

At the day of injection, 200 µl of a suspension containing 51 mg/ml of the microparticles from Example 7 were injected subcutaneously in the neck. The vehicle for the injection was physiological sodium chloride solution containing 3% of sodium carboxymethylcellulose as suspension aid. The injection was made using a 21 G needle. As a control group, non coated microspheres were given to 8 animals for comparison. The insulin dose was 2.5 times higher for the non coated microspheres than for the coated microspheres.

30 Blood samples for measuring blood glucose were taken from the orbital plexus day 0 before insulin dosing and in the afternoon, and at the same times of the day on day 1, 2, 3, 4, 5, 6 and 7 and in the afternoon on day 9 and for the animals given coated microspheres also in the afternoon on day 11. Blood glucose analyses were performed 35 using a commercial kit from Roche on a COBAS MIRA.

FIGURES

The protein releases from the in vitro tests and the BSA concentrations and blood glucose levels from the two in vivo tests are shown in the Figures of the accompanying drawings, wherein

Fig. 1 shows the release from the coated particles of Example 4;

Fig. 2 shows the release from the coated particles of Example 5;

Fig. 3 shows the release from the coated particles of Example 6;

Fig. 4 shows the mean BSA concentrations in serum from the in vivo release for the coated particles of Example 6 and non coated BSA particles;

Fig. 5 shows the mean blood glucose levels from the in vivo release of insulin from the particles of Example 7 and non coated insulin particles.

More specifically the following can be seen from the Figures.

In Fig. 1, the cumulative protein release from the coated particles in Example 4 can be seen. The curves represent different coating levels (weight percent of coating polymer added based on the weight of the core) as indicated in the legend. The core degrades rapidly and releases most of the protein in a very short time. A burst can be seen at all coating levels but is decreased more and more. The coating polymer degrades slowly and therefore no appreciable amount of protein is released after the burst phase.

In Fig. 2, the protein release from the coated particles 40% coating level, as defined above in Example 5 is shown. The polymer is now more easily degraded, giving first a limited burst similar to Example 4 but then after around 2 weeks, the rest of the protein begins to be released from the coated microparticles.

In Fig. 3, protein release from the coated particles (80% coating level, as defined above) from Example 6 can

be seen. In this case, the protein is released more continuously than from Example 4 and 5.

In Fig. 4, the mean BSA concentrations from the in vivo release can be seen. A steady release of BSA is 5 shown during the whole study compared to the non coated microspheres.

In Fig. 5, the mean blood glucose levels from the in vivo release of insulin from the particles of Example 7 and non coated particles are shown. For both preparations, a fast normalisation of the blood glucose level 10 after 6 hours can be seen. After one day, the levels are back to diabetic levels but for the coated preparation, the levels start to decrease again, showing a maximal depression of the blood glucose level after seven days. At 15 day 11, the blood glucose levels are back again to the diabetic state. The insulin has thus retained its biological activity throughout the process and for at least 9 day after injection. For the non coated particles, no delayed effect could be seen.

CLAIMS

1. A method of preparing parenterally administrable, preferably injectionally administrable, sustained release microparticles containing a biologically active substance, which comprises preparing core particles from a biodegradable material in an aqueous medium that is essentially free from organic solvent detrimental to the active substance, the biologically active substance being entrapped therein during or after said preparation, drying the core particles containing said active substance, optionally after a washing step, and coating the core particles with a film-forming, biodegradable, release-controlling polymer by air suspension technique so as to create a shell of said polymer on the core particles without any detrimental exposure of the active substance to organic solvent.

2. A method according to claim 1, wherein microparticles with a mean diameter in the range of 10-200 μm , preferably 20-100 μm , are prepared.

3. A method according to any one of the preceding claims, wherein the core particle material is selected from the group consisting of starches and chemically or physically modified starches.

4. A method according to any one of the preceding claims, wherein the polymer is selected from the group consisting of homo or copolymers prepared from α -hydroxy acids and/or cyclic dimers of α -hydroxy acids.

5. A method according to claim 4, wherein said α -hydroxy acid is selected from the group consisting of lactic acid and glycolic acid.

6. A method according to claim 4, wherein said cyclic dimers are selected from the group consisting of glycolides and lactides.

7. A method according to any one of the preceding claims, wherein the core particles are prepared by using an aqueous two phase system technique.

8. A method according to any one of the preceding claims, wherein the polymer is applied on to the core particles from a solution, a pseudolatex or an emulsion.

5 9. A method according to claim 8, wherein said coating solution contains water, said pseudolatex is a pseudolatex of said polymer in water and said emulsion is an emulsion where one of the phases is a water phase.

10 10. A method according to claim 9, wherein said emulsion is an emulsion where one of the phases is a liquid of the polymer in a solvent therefor and the other phase is water.

15 11. A method according to any one of the preceding claims, wherein the air suspension technique is selected from the group consisting of fluidized bed, including vacuum fluidized bed; spouted bed; and Wurster process techniques.

20 12. A method according to any one of the preceding claims, wherein stabilizing agent(s) for the active substance is(are) incorporated into the core particles during the preparation thereof.

25 13. A method according to any one of the preceding claims, wherein one or more additives are incorporated into the release-controlling polymer shell during the application thereof, which additives are selected from the group consisting of film property modifying agents, such as plasticizers and surfactants, and release controlling agents.

30 14. A method according to any one of the preceding claims, wherein the amount of the polymer shell material is in the range of 1-200% by weight, preferably 5-100% by weight, based on the core weight.

35 15. A method according to any one of the preceding claims, wherein said biologically active substance is a substance that is sensitive to exposure to organic solvent.

16. A method according to claim 15, wherein said active substance is selected from the group consisting of peptides, polypeptides and proteins.


17. A method of coating small particles, preferably 5 microparticles, by air suspension technique, which comprises applying onto said particles, by air suspension technique, a coating emulsion of a coating material where one of the phases is a liquid of said coating material in a solvent and the other phase is water.

10 18. Parenterally administrable, preferably injectionally administrable, sustained release microparticles containing a biologically active substance, which comprise a) core particles of a biodegradable material with the active substance entrapped therein, which core particles have been prepared in an aqueous medium essentially 15 free from organic solvent detrimental to the active substance and b) a shell of a film-forming, biodegradable, release-controlling polymer on said core particles, which shell has been applied on said core particles by air suspension technique.

20 19. Microparticles according to claim 18, which have been prepared as defined in any one of claims 2-16.


1/5

Fig. 1




2/5

Fig. 2




3/5

Fig. 3




4/5

Fig. 4



5/5

Fig. 5



INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 96/01091

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI, EMBASE, MEDLINE, IFIPAT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0535937 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 7 April 1993 (07.04.93) --	1-19
A	US 4568559 A (ELIE S. NUWAYSER ET AL), 4 February 1986 (04.02.86) -----	1-19

Further documents are listed in the continuation of Box C.

See patent family annex.

- Special categories of cited documents
- “A” document defining the general state of the art which is not considered to be of particular relevance
- “B” earlier document but published on or after the international filing date
- “C” document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- “D” document referring to an oral disclosure, use, exhibition or other means
- “E” document published prior to the international filing date but later than the priority date claimed

- “F” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- “G” document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- “H” document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- “I” document member of the same patent family

Date of the actual completion of the international search

21 January 1997

Date of mailing of the international search report

01-02-1997

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-1C2 42 STOCKHOLM
Facsimile No. -46 8 666 00 36

Authorized officer
Eva Johansson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/01091

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
EP-A1- 0535937	07/04/93		CA-A- 2079509 JP-A- 5194200		02/04/93 03/08/93
US-A- 4568559	04/02/86		US-A- 4623588		18/11/86